Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The product is used to treat amyotrophic lateral sclerosis
The Product is expected to be the first generic approval on the market
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
Subscribe To Our Newsletter & Stay Updated